SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Werewolf Therapeutics, Inc. (HOWL) News

Track canonical SquawkNews coverage tagged to HOWL, Werewolf Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol HOWL Asset equity Sector Markets 90 days 6 Last 0.7616 Updated Aug 21, 2026, 09:17 AM UTC Open live news feed
M Premarket gainers list led by RFAI, RFAIR and HOWL TradeXchange Newsdesk lists the top ten premarket percentage gainers, led by RFAI at +411.70%, RFAIR at +125.00% and HOWL at +76.57%, with no catalyst supplied. EQUITY | Aug 21, 2026, 09:17 AM UTC M Werewolf Therapeutics obtains exclusive EMD license for WTX-124, WTX-330 Hammerstone MarketTalk reports that HOWL Werewolf Therapeutics obtains an exclusive license from EMD for the development of WTX-124 and WTX-330, as stated in an SEC filing. REGULATION | Aug 20, 2026, 08:08 PM UTC M Werewolf Therapeutics files EMD deal for $28M upfront payment Werewolf Therapeutics (HOWL) files an SEC disclosure stating EMD will pay $28M upfront and $5M upon completion of asset transfer, with terms tied to the asset move. MNA | Aug 20, 2026, 08:08 PM UTC M Werewolf Therapeutics sells inducer and indukine platforms to EMD Serono Werewolf Therapeutics says in an SEC filing that it sold its inducer and indukine platforms to EMD Serono on August 14. MNA | Aug 20, 2026, 08:08 PM UTC L HOWL Werewolf Therapeutics RESULTS: Q2, Q2 basic EPS $0.08, Q2 Net Income $3.67M, Q2 operating expenses $13.842M, Q2 collaboration REV $21M, HOWL Werewolf Therapeutics RESULTS: Q2, Q2 basic EPS $0.08, Q2 Net Income $3.67M, Q2 operating expenses $13.842M, Q2 collaboration REV $21M, Q2 Operating Income $7.158M EARNINGS | Jul 31, 2026, 11:01 AM UTC L HOWL - Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates HOWL - Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates EARNINGS | Jul 31, 2026, 11:00 AM UTC